These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 7796290)

  • 21. [Management of a hormone dependent cancer with endocrine therapy--prostate cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 2001 Jul; 28(7):917-26. PubMed ID: 11478140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer.
    Roach M
    Eur Urol; 1997; 32 Suppl 3():48-54. PubMed ID: 9267785
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Endocrine therapy for localized or locally advanced prostate cancer].
    Fontaine E; Ruffion A; Staerman F
    Prog Urol; 2004 Jun; 14(3):433-6. PubMed ID: 15373195
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials.
    Halabi S; Vogelzang NJ; Ou SS; Small EJ
    J Urol; 2007 Feb; 177(2):531-4. PubMed ID: 17222627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer].
    Akaza H; Hirao Y; Labrie F; Soloway MS
    Hinyokika Kiyo; 2003 Dec; 49(12):771-7. PubMed ID: 14978964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intermittent complete androgen blockade in PSA relapse after radical prostatectomy and incidental prostate cancer.
    Kurek R; Renneberg H; Lübben G; Kienle E; Tunn UW
    Eur Urol; 1999; 35 Suppl 1():27-31. PubMed ID: 10081700
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Neoadjuvant hormone therapy before prostatectomy for cancer localized to the prostate].
    Boccon-Gibod L
    Prog Urol; 1997 Feb; 7(1):97-8. PubMed ID: 9116748
    [No Abstract]   [Full Text] [Related]  

  • 28. Radical prostatectomy and early adjuvant hormonal therapy for pTxN+ adenocarcinoma of the prostate.
    Seay TM; Blute MC; Zincke H
    Urology; 1997 Dec; 50(6):833-7. PubMed ID: 9426709
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical impact of neoadjuvant treatment to radical prostatectomy in locally advanced prostatic cancer].
    Villavicencio H; Laguna P; Ponce de Léon J
    Actas Urol Esp; 1994 May; 18 Suppl():404-8. PubMed ID: 8073926
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of hospital volume on cancer control after radical prostatectomy.
    Ellison LM; Trock BJ; Poe NR; Partin AW
    J Urol; 2005 Jun; 173(6):2094-8. PubMed ID: 15879850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant medical therapy for prostate cancer.
    Sumey C; Flaig TW
    Expert Opin Pharmacother; 2011 Jan; 12(1):73-84. PubMed ID: 21118060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of endocrine therapy in the management of local and distant recurrence of prostate cancer following radical prostatectomy or radiation therapy.
    Mayer FJ; Crawford ED
    Urol Clin North Am; 1994 Nov; 21(4):707-15. PubMed ID: 7974899
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does neoadjuvant hormone therapy improve outcome in prostate cancer patients receiving radiotherapy after radical prostatectomy?
    Pai HH; Eldridge B; Bishop D; Alexander A; Lesperance M; Blood P; Lim J; Ludgate C
    Can J Urol; 2009 Apr; 16(2):4541-52. PubMed ID: 19364426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of prostate cancer].
    Imre R
    Orv Hetil; 2005 Aug; 146(35):1839-42. PubMed ID: 16187544
    [No Abstract]   [Full Text] [Related]  

  • 35. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J
    Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neoadjuvant androgen deprivation for prostate volume reduction: the optimal duration in prostate cancer radiotherapy.
    Langenhuijsen JF; van Lin EN; Hoffmann AL; Spitters-Post I; Alfred Witjes J; Kaanders JH; Mulders PF
    Urol Oncol; 2011; 29(1):52-7. PubMed ID: 19523856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Combined radiotherapy and hormone therapy in non-metastatic adenocarcinoma of prostate].
    Lopez S; Simon JM; Mazeron JJ
    Bull Cancer; 2009 Mar; 96(3):261-70. PubMed ID: 19318304
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Innovative approaches to the hormonal treatment of advanced prostate cancer.
    Trachtenberg J
    Eur Urol; 1997; 32 Suppl 3():78-80. PubMed ID: 9267790
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Managing prostate cancer: the role of hormone therapy.
    Ramirez ML; Keane TE; Evans CP
    Can J Urol; 2007 Dec; 14 Suppl 1():10-8. PubMed ID: 18163939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.